Recruiting NCT05370079
Control Cohort CTRL COH
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Collection of biological sample (blood and/or CSF).
- Who it may be relevant to
- Registry conditions: Parkinson's Disease; Amyotrophic Lateral Sclerosis; Glioblastoma; Cancer Without Neurological Disease; Rheumatoid Polyarthritis. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Autoimmune encephalitis (AE) and paraneoplastic neurological syndromes (PNS) are rare disease that could be difficult to diagnose. So it necessary to obtain numerous sample from different disease to develop more specific diagnosis kit It could be possible through the characterisation of new genetic biomarkers.
Interventions
- Biological Collection of biological sample (blood and/or CSF)
Blood sample will be collected one time for each patient: 2 \*4ml of blood on dry tube 2 \*4ml of blood on EDTA tube If cerebrospinal fluid (CSF) has been drawn for diagnosis, remaining sample available will be stored in the control cohort (1 ml).
Primary outcome measures
- Samples (blood dry and EDTA tube and optional cerebro-spinal-fluid) [Time frame: 15 minutes]
Secondary outcome measures (1)
- Description of genetic analysis [Time frame: Data collecting: 3 years Data analysis: 2 years]
Eligibility criteria
Inclusion criteria
- patient with consent
- patient with following disease: Parkinson's disease, Amyotrophic lateral sclerosis, Glioblastoma, cancer without neurological disease (pulmonary cancer, breast cancer, ovarian cancer, melanoma, thymoma), rheumatoid arthritis.
Exclusion criteria
- refusal consent
- patient with neurological disorder compatible with paraneoplastic neurological syndrome or auto-immune encephalitis
- patient under guardianship
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Diagnostic
Study locations
France · 1 center
- Hospices Civils de Lyon — Bron
Identifiers
NCT: NCT05370079 · 69HCL22_0275